initial public offerings (IPOs) trading on American exchanges

Wednesday, November 20, 2024

Forte Biosciences (FBRX) : 7-year performance

Note: Forte Biosciences was acquired by the global immunology company argenx SE (ARGX) in a cash tender offer and merger valued at approximately $2.2 billion ($77.00 per share).  (August 2026)

 



No comments:

Post a Comment